New weapon against tough blood cancers: scientists test Next-Gen cell therapy
NCT ID NCT07135466
Summary
This study is testing a new type of personalized cell therapy called CD22 CAR-T for patients whose B-cell blood cancers have come back or not responded to other treatments, including other CAR-T therapies. Doctors will collect a patient's own immune cells, genetically modify them to target a protein called CD22 on cancer cells, and infuse them back. The main goals are to see if this approach is safe and if it can help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B CELL MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sheba Medical Center
RECRUITINGRamat Gan, G, Israel
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.